- Home
- GILD vs LOW Comparison
GILD vs LOW Comparison
Compare GILD & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- LOW
- Stock Information
- Founded
- GILD 1987
- LOW 1946
- Country
- GILD United States
- LOW United States
- Employees
- GILD N/A
- LOW 270000
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- LOW RETAIL: Building Materials
- Sector
- GILD Health Care
- LOW Consumer Discretionary
- Exchange
- GILD Nasdaq
- LOW Nasdaq
- Market Cap
- GILD 147.6B
- LOW 133.5B
- IPO Year
- GILD 1992
- LOW N/A
- Fundamental
- Price
- GILD $127.67
- LOW $242.53
- Analyst Decision
- GILD Buy
- LOW Buy
- Analyst Count
- GILD 22
- LOW 20
- Target Price
- GILD $123.45
- LOW $273.15
- AVG Volume (30 Days)
- GILD 7.6M
- LOW 3.5M
- Earning Date
- GILD 10-30-2025
- LOW 11-19-2025
- Dividend Yield
- GILD 2.48%
- LOW 1.99%
- EPS Growth
- GILD 6514.05
- LOW 0.70
- EPS
- GILD 6.42
- LOW 12.06
- Revenue
- GILD $29,087,000,000.00
- LOW $84,255,000,000.00
- Revenue This Year
- GILD $3.05
- LOW $2.74
- Revenue Next Year
- GILD $3.29
- LOW $6.25
- P/E Ratio
- GILD $19.85
- LOW $20.03
- Revenue Growth
- GILD 2.79
- LOW 0.64
- 52 Week Low
- GILD $88.57
- LOW $206.39
- 52 Week High
- GILD $128.70
- LOW $280.64
- Technical
- Relative Strength Index (RSI)
- GILD 60.74
- LOW 56.66
- Support Level
- GILD $124.49
- LOW $228.73
- Resistance Level
- GILD $128.25
- LOW $236.56
- Average True Range (ATR)
- GILD 3.43
- LOW 5.46
- MACD
- GILD 0.17
- LOW 1.61
- Stochastic Oscillator
- GILD 91.36
- LOW 95.67
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About LOW Lowe's Companies Inc.
Lowe's is the second-largest home improvement retailer globally, with around 1,750 stores in the US, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past six years (set ot expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.